Document is current
Any future updates will be listed below
-
Authors
Tunbridge, Elizabeth M. https://orcid.org/0000-0002-2966-2281
Carr, Gregory V. https://orcid.org/0000-0002-6091-6729
Weinberger, Daniel R. https://orcid.org/0000-0003-2409-2969
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH132019)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH137057)
Lieber Institute for Brain Development
- License Information
-
More Information
Article History
Received: 24 March 2026
Revised: 29 July 2026
Accepted: 7 August 2026
First Online: 19 August 2026
Ethics
Competing interests: EMT is a full-time employee of Boehringer Ingelheim and has previously provided consultancy to Boehinger Ingelheim and ONO Pharma, and received unrestricted educational funding from J&J Innovations, and Boehringer Ingelheim and Biogen via the Psychiatry Consortium of the Medicines Discovery Catapult. GVC is a scientific advisor for LongTermGevity, Inc. and owns stock options in the company. DRW is on the Scientific Advisory Board (SAB) of Pasithea Therapeutics, and until September, 2025, had been on the SAB of Sage Therapeutics.
